Hexoprenaline

Hexoprenaline is an orally active and selective β-adrenergic receptor agonist. Hexoprenaline can dilate the bronchi. Hexoprenaline can activate adenylate cyclase and increases 14C-Aminopyrine uptake. Hexoprenaline exhibits anti-infection and anti-inflammmation effect. Hexoprenaline can increase placental weight and blood flow. Hexoprenaline can be used for the researches of inflammation, immunology, infection, endocrinology and neurological disease, such as asthma, chronic bronchitis, sepsis and intoxication of organophosphorus compounds[1][2][3][4][5].

Product Specifications

CAS Number

[3215-70-1]

UNSPSC

12352005

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Infection; Endocrinology; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/hexoprenaline.html

Purity

96.0

Solubility

10 mM in DMSO

Smiles

OC(CNCCCCCCNCC(O)C1=CC=C(C(O)=C1)O)C2=CC=C(C(O)=C2)O

Molecular Formula

C22H32N2O6

Molecular Weight

420.50

References & Citations

[1]Schonell M, et al. Bronchodilator effect of hexoprenaline aerosol in bronchial asthma and chronic bronchitis. Med J Aust. 1977 Dec 17;2 (25) :828-30.|[2]Ruoff HJ, et al. Adrenergic stimulation of isolated rat gastric mucosal cells. Effect on adenylate cyclase and 14C-aminopyrine uptake. Naunyn Schmiedebergs Arch Pharmacol. 1982 Aug;320 (2) :175-81.|[3]Zabrodskii P F. et al. The Mechanisms of the Cholinergic Anti-Inflammatory Pathway after Acute Intoxication of Organophosphorus Compounds[J]. Biomedical Journal, 2010, 1: 5.|[4]Zabrodskii P F. et al. The influence of various drugs on mortality of mice and the concentration of proinflammatory cytokines in blood at sepsis caused by E. coli[J]. Acta scientific microbiology, 2018, 1: 11-14.|[5]Lipshitz J, et al. Effect of long-term administration of beta 2-sympathomimetic drug in the diet-restricted pregnant rat model. Am J Obstet Gynecol. 1986 Feb;154 (2) :314-7.